Decrease in ADAR1 expression by exposure to cigarette smoke enhances susceptibility to oxidative stress.


Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
01 Oct 2020
Historique:
received: 04 02 2020
revised: 11 05 2020
accepted: 14 05 2020
pubmed: 23 5 2020
medline: 24 7 2020
entrez: 23 5 2020
Statut: ppublish

Résumé

Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes, is the most frequent type of post-transcriptional nucleotide conversion in humans. It is known that innate abnormalities of A-to-I RNA editing are associated with the risk of certain diseases, such as amyotrophic lateral sclerosis. Extrinsic factors that modulate ADAR-mediated RNA editing remain to be clarified. In this study, we investigated the possibility that cigarette smoking may influence the expression of ADAR and that the changes may be biologically significant. Treatment of human lung adenocarcinoma A549 cells with cigarette smoke extract (CSE) induced a significant 50% decrease in ADAR1 protein levels. Since the decrease was counteracted by cotreatment with chloroquine, the CSE-dependent decrease in the ADAR1 protein levels may be due to the activation of autophagy. In addition to the in vitro study, we performed an in vivo study in mice and found a decrease in pulmonary Adar1 protein expression induced by cigarette smoking. Then, we investigated the biological significance of decreased ADAR1 expression. We found that knockdown of ADAR1 in A549 cells by siRNA resulted in an increase in the levels of protein carbonyl, a marker of oxidative stress. Moreover, knockdown of ADAR1 triggered a decrease in super oxide dismutase activity and heme oxygenase-1 expression, suggesting that ADAR1 plays a role to suppress oxidative stress. In conclusion, we show that ADAR1 expression is decreased by cigarette smoking and is a factor that contributes to the enhanced intracellular oxidative stress caused by cigarette smoking.

Identifiants

pubmed: 32439581
pii: S0378-4274(20)30168-5
doi: 10.1016/j.toxlet.2020.05.019
pii:
doi:

Substances chimiques

RNA-Binding Proteins 0
Smoke 0
ADAR protein, human EC 3.5.4.37
Adenosine Deaminase EC 3.5.4.4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

22-32

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Masashi Takizawa (M)

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Japan.

Masataka Nakano (M)

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.

Tatsuki Fukami (T)

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.

Miki Nakajima (M)

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. Electronic address: nmiki@p.kanazawa-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH